Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29178346 | 0.90 | AOC3 (0.53) | AOC3SIGMAR1TACR1 | |
| SCHEMBL29178344 | 0.90 | AOC3 (0.53) | AOC3SIGMAR1TACR1 | |
| SCHEMBL1414607 | 0.87 | MLYCD (0.49) | MLYCDAOC3TAAR1LIPEHPGD | |
| SCHEMBL13181376 | 0.86 | MLYCD (0.54) | MLYCDAOC3TAAR1LIPEHPGD | |
| SCHEMBL17152628 | 0.84 | AOC3 (0.49) | MLYCDAOC3TAAR1LIPEHPGD | |
| SCHEMBL27734471 | 0.84 | TACR1 (0.51) | MLYCDAOC3TAAR1SIGMAR1TACR1 | |
| SCHEMBL1007948 | 0.83 | HPGD (0.68) | HPGDKMT2A | |
| SCHEMBL3220549 | 0.83 | HPGD (0.68) | HPGDKMT2A | |
| SCHEMBL1007950 | 0.83 | HPGD (0.68) | HPGDKMT2A | |
| SCHEMBL11712667 | 0.83 | MLYCD (0.48) | MLYCDAOC3TAAR1LIPETACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2310368-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009147221-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | MLYCD 1254/4885AOC3 4527/4885TAAR1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.